Clinical trials: CTEPH
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)
The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic…
- Trial name
- CTREPH (NCT01416636)
- Testing
- Treprostinil sodium
- Where
- 6 sites in Austria, Czechia and 2 more
- Volunteers
- 105 people
- Sponsor
- SciPharm SàRL
Chronic Thromboembolic Pulmonary Hypertension
The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling.
- Trial name
- NCT04773028
- Testing
- matrix metalloproteinase enzymes 2 and 9
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- AHMET ZENGIN
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Hypertension
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed treatment options exist.
- Trial name
- AMBER I (NCT01884675)
- Testing
- Ambrisentan 5 mg
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Hypertension
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
This is an open label, long term extension to Study AMB115811. All subjects may remain in the extension study for a minimum of 18 months.
- Trial name
- AMBER II (NCT01894022)
- Testing
- Ambrisentan 5 mg
- Where
- 50 sites in United States, Argentina and 14 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- CHEST-2 (NCT00910429)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 73 sites in United States, Argentina and 24 more
- Volunteers
- 237 people
- Sponsor
- Bayer
CTEPH, Pulmonary Embolism
CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients
In this study the investigators will evaluate whether more careful reading (than the current standard) of routine computerised tomography pulmonary angiography (CTPA) performed in the clinical work-up of suspected (pulmonary…
- Conditions
- CTEPH, Pulmonary Embolism, Early Diagnosis
- Trial name
- InShapeIII (NCT03083093)
- Testing
- The initial CTPA will be reviewed
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Leiden University Medical Center
Cardiomyopathy, Cardiac Arrhythmia
RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators
If a surgical sponge is mistakenly left inside a patient's body after a surgical procedure, it can cause a serious infection. To prevent this from happening, a new device has been developed that uses radiofrequency (RF) signals…
- Conditions
- Cardiomyopathy, Cardiac Arrhythmia, Heart Failure, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- RF (NCT02111980)
- Testing
- RF Assure Scanning
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Chronic Thromboembolic Pulmonary Hypertension
Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Study to evaluate if macitentan is efficient, safe and tolerable enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- MERIT-1 (NCT02021292)
- Testing
- Macitentan
- Where
- 36 sites in Belgium, China and 14 more
- Volunteers
- 80 people
- Sponsor
- Actelion
Pulmonary Hypertension
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
- Trial name
- BENEFIT OL (NCT00319111)
- Testing
- bosentan
- Volunteers
- 151 people
- Sponsor
- Actelion
Chronic Thromboembolic Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- MACiTEPH (NCT04271475)
- Testing
- Macitentan
- Where
- 168 sites in United States, Argentina and 31 more
- Volunteers
- 127 people
- Sponsor
- Actelion
Chronic Thromboembolic Pulmonary Hypertension
Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
- Trial name
- MERIT-2 (NCT02060721)
- Testing
- Macitentan
- Where
- 33 sites in Belgium, China and 13 more
- Volunteers
- 76 people
- Sponsor
- Actelion
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
This is a randomised, double-blind, placebo-controlled, multicentre, multinational, prospective study in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) prior to pulmonary endarterectomy (PEA) with…
- Trial name
- NCT03273257
- Testing
- Riociguat, Pulmonary endarterectomy
- Where
- 4 sites in United States, France and 2 more
- Volunteers
- 14 people
- Sponsor
- International CTEPH Association